154-85-8

Usage

Uses

Used in Pharmaceutical Industry:
6-CARBOXY-2,4-DIHYDROXYPYRIMIDINE MONOSODIUM SALT is used as a complex-forming agent for [forming a complex with lanthanum(III)] for [displaying cytotoxic activity on different tumor cell lines].
Used in Synthesis of Labeled Compounds:
6-CARBOXY-2,4-DIHYDROXYPYRIMIDINE MONOSODIUM SALT is used as an intermediate for [synthesis of Orotic Acid-15N2 Monosodium Salt (O691517)] for [further synthesis of Orotic Acid-15N2 Monohydrate (O691504), a labeled analogue of Orotic Acid Monohydrate (O691500)].
Used in Chronic Obstructive Pulmonary Disease (COPD) Treatment:
6-CARBOXY-2,4-DIHYDROXYPYRIMIDINE MONOSODIUM SALT is used as a precursor for [preparation of therapeutic agents] for [treatment of chronic obstructive pulmonary disease (COPD)].

InChI:InChI=1/C5H4N2O4.Na/c8-3-1-2(4(9)10)6-5(11)7-3;/h1H,(H,9,10)(H2,6,7,8,11);/q;+1/p-1

Upstream product

• 65-86-1 orotic acid 
• 626-48-2 6-Methyluracil 
• 62881-01-0 6-trichloromethyl-1H-pyrimidine-2,4-dione 

Downstream Products

• 58-32-2 dipyridamole 
• 17687-24-0 5-nitroorotic acid 
• 7164-43-4 5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid 
• 6713-54-8 2,4,6,8-tetrahydroxypyrimidine-[5,4-d]pyrimidine 
• 32980-71-5 2,4,6,8-Tetrachloro-pyrimido[5,4-d]pyrimidine 
• 7139-02-8 2,6-dichloro-4,8-bis(piperidin-1-yl)pyrimido[5,4-d]pyrimidine 
• 3387-36-8 disodium uridine-5'-monophosphate 

Relevant academic research and scientific papers

Tri- and diorganotin(IV) complexes of biologically important orotic acid: Synthesis, spectroscopic studies, in vitro anti-cancer, DNA fragmentation, enzyme assays and in vivo anti-inflammatory activities

Tri-and diorganotin(IV) orotates of general formula, RnSn(H 2Or)m [n = 3/2, m = 1/2, R = Me, n-Bu, n-Oct and Ph; H2Or- = monoanion of orotic acid (H3Or)] (n-Bu2Sn(HOr) as an exception) have been synthesized. On the basis of various spectroscopic studies it is revealed that R3Sn(H 2Or) and R2Sn(H2Or)2 exhibit distorted trigonal-bipyramidal and distorted octahedral geometry, respectively, and n-Bu2Sn(HOr) shows both five and six coordination geometry around tin. In vitro anti-cancer screening against MCF-7 (mammary), HEK-293 (kidney), PC-3 (prostate), HCT-15 (colon) and HepG-2 (liver) cancer cell lines suggest that the n-Oct2Sn(H2Or)2 is the most active complex among all of the studied complexes. DNA fragmentation and antioxidant enzyme assays suggest that cytotoxic effect of the complexes is selectively mediated through the induction of apoptosis. They also exhibit low toxicity and good anti-inflammatory activity (in vivo).

Production method of dipyridamole bulk drug

The invention provides a production method of a bulk drug of dipyridamole, which relates to the field of the synthesis of chemical bulk drugs. The production method comprises the following steps: protecting carbonyl of urea, performing condensation reaction with 2,3-diaminosuccinic acid, performing chlorination for hydroxyl of a condensation reactant, replacing chlorine with piperidine, hydrolyzing an obtained product, obtaining a compound containing two carbonyls, separating the product, enabling the separated product to have condensation reaction with diethanol amine, obtaining dipyridamole,and refining to obtain a finished product. By adopting the production method, the synthetic procedure of the dipyridamole is simplified, the conversion rate of raw materials can be greatly increased,and the production cost is decreased.

Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives

This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous tissues. There orotate derivatives are equally efficacious in inhibiting the SCCAKI-1 kidney tumor in animals and the reduction in the heart tissue of doxorubicin compared with doxorubicin HCl suggests a reduction in toxicity induced by free radical generation by the anthrracyclines.

Process for the production of orotic acid

A process for the trichloroacetyl of orotic acid which comprises (a) converting trichloroacetyl chloride to γ, γ, γ-trichloroacetoacetyl chloride with ketene, (b) adding reaction mixture (a) to urea dissolved in a polar organic solvent, e.g., acetic acid, 6-trichloromethyluracil being produced, (c) separating the 6-trichloromethyluracil from reaction mixture (b), and (d) hydrolyzing the 6-trichloromethyluracil to orotic acid.

Process for preparing orotic acid

A method for the preparation of orotic acid and thioorotic acid is described which includes the formation of carboxymethylene-hydantoin or -thiohydantoin and subsequent rearrangement and isolation of orotic acid and thioorotic acid, respectively.